Theriva Biologics Q1 2024 GAAP EPS $(0.30) Misses $(0.27) Estimate
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics reported a Q1 2024 GAAP EPS of $(0.30), missing the estimated $(0.27) by $0.03.
May 07, 2024 | 11:14 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Theriva Biologics' Q1 2024 earnings miss could lead to negative investor sentiment and potential short-term price pressure.
Earnings misses often result in negative short-term market reactions as they may indicate operational or financial challenges. Given the miss, investors might reassess the company's growth prospects, leading to potential sell-offs.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100